11 results about "CagA" patented technology

The embodiment of the invention discloses a primer group and application. Specific primers are designed for a UreA gene, a GyrA gene, a 23SrRNA gene, a PbP1 gene, a 16SrRNA gene, a porD gene, a CagA gene, a vacA gene, a CYP2C19 * 2 gene, a CYP2C19 * 3 gene, a CYP2C19 * 17 gene and mutation sites on the basis of a nucleic acid mass spectrometry technology, the helicobacter pylori detection kit has the advantages of high sensitivity and high accuracy, and helicobacter pylori identification, antibiotic sensitivity / drug resistance detection and virulence gene typing can be quickly and efficiently carried out; the method for detecting the metabolic type of the proton pump inhibitor has a good application prospect.

The invention relates to the technical field of biology, in particular to a helicobacter pylori antibody typing reagent combination as well as a preparation method and application of the helicobacter pylori antibody typing reagent combination. Comprising an acridinium ester mouse anti-human IgG complex solution, a biotin-Ure recombinant protein complex solution, a biotin-CVfp fusion protein complex solution and a streptavidin magnetic bead mother solution. The biotin-Ure recombinant protein complex liquid is obtained by labeling Ure recombinant protein with biotin, and the amino acid sequence of the Ure recombinant protein is as shown in SEQ ID No. 1; the biotin-CVfp fusion protein complex liquid is obtained by labeling CVfp fusion protein with biotin, the CVfp fusion protein carries out fusion expression on antigen epitopes of CagA and VacA, and the amino acid sequence of the CVfp fusion protein is shown as SEQ ID No.2. The problems that at present, Hp virulence factor typing detection indexes are complex, reagent cost is high, and detection flux is low are solved.

The present application relates to a fusion protein and its application in detection of Helicobacter pylori CagA antibody, and belongs to the technical field of biology.The present application provides a fusion protein, wherein the fusion protein comprises a polypeptide with an amino acid sequence as shown in SEQ ID NO.1, or a derivative polypeptide with more than 80% homology with the amino acid sequence as shown in SEQ ID NO.1 and capable of being specifically combined with Helicobacter pylori CagA antibody; the fusion protein is capable of being specifically combined with Helicobacter pylori CagA antibody, and has a very high application prospect in detection of Helicobacter pylori CagA antibody.

According to the anti-helicobacter pylori CagA subtype antibody detection kit and the application thereof provided by the invention, CagA subtype protein is optimized and screened to obtain a truncated fragment containing two dominant epitope targets, expression of different systems is performed to obtain a CagA subtype recombinant antigen fragment, the antigen fragment is utilized to screen an antibody as a quality control standard substance, and the detection kit is used for detecting the helicobacter pylori CagA subtype antibody. A chemiluminescence detection kit is developed, and whether a body is infected with helicobacter pylori or not can be rapidly detected.

There is provided novel peptides for use in diagnosis of CagA+ H. pylori infection or the prediction of risk for gastric cancer. The peptides bind antibodies from CagA+ H pylori patients with high specificity and sensitivity, and can be used for example in a diagnostic kit.

: Title: Antibacterial Application of Pyrrolidin-Piperdine Derivatives Containing Composition to Inhibit Helicobacter Pylori Replication, Preparation Method Thereof The present disclosure proposes a method for identification, optimizing, and preparing a therapeutic molecule (MA01027) for inhibiting cytotoxin-associated gene A (CagA) protein of Helicobacter pylori. The therapeutic molecule specifically targets and binds to a particular protein of interest, thereby enhancing the efficacy and specificity of the treatment. The therapeutic molecule is optimized for its binding affinity and selectivity for the target protein. The therapeutic molecule involves combining specific reactants under controlled conditions to achieve high yields and purity of the therapeutic molecule. The therapeutic molecule preparation includes purification steps to isolate the therapeutic molecule from the reaction mixture using standard techniques, thereby ensuring a high-quality final product. The therapeutic molecule binds to the CagA protein of H. pylori, inhibiting its replication by more than 90% and eliminating H. pylori-associated hemolysis.

This invention provides a multiplex nucleic acid detection primer for Helicobacter pylori, including primers targeting Helicobacter pylori 16S rRNA, shit , cow Gene-designed 16S rRNA primer pairs, shit Primer pairs, cow Primer pairs. This invention also provides detection probes, including gold nanoparticle capture probes, 16S rRNA capture probes, and... shit Capture probe, cow Capture probes and quality control capture probes. This invention also provides the above primers and probes for the preparation of Helicobacter pylori 16S rRNA, shit , cow Applications of gene detection products, as well as detection kits and methods. This invention can detect Helicobacter pylori 16S rRNA. 、cagA , cow Simultaneous detection of three genes and virulence typing, with highly specific primers and probes, stable amplification, high sensitivity, simple operation, short time consumption, and low cost, is suitable for rapid screening in clinical settings and on-site.

The invention discloses a detection kit suitable for helicobacter pylori virulence genotyping / mutation and drug-resistant gene mutation in an excrement sample and a signal calculation method. The kit comprises a primer / probe / capture probe for specifically detecting the following genes or mutation sites or polymorphisms on the genes: an infectious gene, a virulence typing gene (VacA / CagA / CagL / HtrA), a clarithromycin drug-resistant gene, a tetracycline drug-resistant gene, a levofloxacin drug-resistant gene, an amoxicillin drug-resistant gene, a metronidazole drug-resistant gene and a furazolidone drug-resistant gene, the kit comprises a cytochrome P450 enzyme 2C19 gene and an exogenous internal standard primer / probe / capture probe. The signal calculation method can make the detection result more intelligent and standardized. According to the kit, one-time polymorphism detection of helicobacter pylori infection, virulence typing, drug resistance type and proton pump inhibitor related metabolic genes can be achieved from samples such as excrement and gastric mucosa of a patient, and hierarchical management and radical treatment of helicobacter pylori can be achieved clinically in an auxiliary mode.

The present invention relates to a nucleic acid aptamer CAGA03 of Helicobacter pylori CagA and an application thereof, and belongs to the field of biotechnology. The present invention uses an in vitro SELEX screening technology, carboxyl magnetic beads as a solid phase medium, takes Helicobacter pylori CagA protein as a target, and obtains a nucleic acid aptamer specifically binding to Helicobacter pylori CagA from a ssDNA library through Helicobacter pylori CagA magnetic beads; the nucleic acid aptamer CAGA03 of the present invention can bind to Helicobacter pylori CagA protein with high affinity and high specificity, and the nucleic acid aptamer CAGA03 provides a new choice for preparing a detection reagent, a purification reagent, a targeting vector and an antagonist of Helicobacter pylori CagA protein.

The present invention provides an anti-Helicobacter pylori CagA subtype antibody detection kit and its application. CagA subtype proteins are optimized and screened to obtain truncated fragments containing two dominant epitope targets. These fragments are expressed in different systems to obtain CagA subtype recombinant antigen fragments. The antigen fragments are used to screen antibodies as quality control standards, and a chemiluminescence detection kit is developed to quickly detect whether an organism is infected with Helicobacter pylori.

The application relates to the field of biotechnology, in particular to a Helicobacter pylori antibody typing reagent combination and a preparation method and application thereof, a magnetic particle chemiluminescence reagent combination for Helicobacter pylori antibody typing, which comprises an acridinium ester mouse anti-human IgG complex solution, a biotin-Ure recombinant protein complex solution, a biotin-CVfp fusion protein complex solution and a streptavidin magnetic bead mother liquor; the biotin-Ure recombinant protein complex solution is obtained by marking Ure recombinant protein with biotin, the amino acid sequence of the Ure recombinant protein is shown as SEQ ID No. 1; the biotin-CVfp fusion protein complex solution is obtained by marking CVfp fusion protein with biotin, the CVfp fusion protein is fused and expressed to antigen epitopes of CagA and VacA, the amino acid sequence of the CVfp fusion protein is shown as SEQ ID No. 2, and the problems of complex detection indexes, high reagent cost and low detection flux for current Hp virulence factor typing are solved.